Composition and method for muscle repair and regeneration
AssigneeThomas Jefferson University
InventorsMasahiro Iwamoto, Maurizio Pacifici
Life of this patent
Estimating the term…
Abstract
The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RARγ agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue.
Claims23
A method of muscle repair or regeneration in a subject with damaged muscle tissue, comprising administering a therapeutically effective amount of a retinoic acid receptor gamma (RARγ) agonist to a subject with damaged muscle tissue, to thereby repair or regenerate the damaged muscle tissue, wherein the RARγ agonist is 4-[(E)-2-[5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-3-(1H-pyrazol-1-ylmethyl)-2-naphthalenyl]-ethenyl]-benzoic acid or a pharmaceutically acceptable salt thereof.
A method of inducing progenitor stem cells to undergo myogenic differentiation in a subject with damaged muscle tissue, comprising administering a therapeutically effective amount of an RARγ agonist to the subject, wherein the RARγ agonist is 4-[(E)-2-[5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-3-(1H-pyrazol-1-ylmethyl)-2-naphthalenyl]-ethenyl]-benzoic acid or a pharmaceutically acceptable salt thereof.
A method for reducing muscle tissue damage in a subject with a muscle damaging myopathy, said method comprising administering to said subject an RARγ agonist in amount sufficient to reduce said muscle tissue damage wherein the RARγ agonist is 4-[(E)-2-[5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-3-(1H-pyrazol-1-ylmethyl)-2-naphthalenyl]-ethenyl]-benzoic acid or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.